quinazolines has been researched along with Urination Disorders in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (15.00) | 18.7374 |
| 1990's | 11 (27.50) | 18.2507 |
| 2000's | 20 (50.00) | 29.6817 |
| 2010's | 3 (7.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaplan, SA | 1 |
| Athanasopoulos, A; Giannitsas, K; Gyftopoulos, K; Perimenis, P | 1 |
| Calleja Aguayo, E; Delgado Alvira, R; Gracia Romero, J; Rihuete Heras, MA; Ruiz de Temiño Bravo, M | 1 |
| Akyüz, M; Güneş, M; Kalkan, S; Karaman, MI; Koca, O; Öztürk, Mİ | 1 |
| Brown, GA; Sussman, DO | 1 |
| de Reijke, TM; Klarskov, P | 1 |
| Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, RJ | 1 |
| Akbay, E; Bozlu, M; Cayan, S; Görür, S; Ulusoy, E | 1 |
| Nordling, J | 1 |
| Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, J | 2 |
| Casey, R; Elhilali, M; Kuzmarov, I; Nickel, JC; Saad, F; Valiquette, L | 1 |
| Seftel, A | 1 |
| MacDonald, R; Wilt, TJ | 1 |
| Armitage, JN; Emberton, M | 1 |
| Alcaraz, A; Elhilali, M; Emberton, M; Lukacs, B; Matzkin, H; Vallancien, G | 1 |
| Gonzalez, RR; Kaplan, SA; Te, AE | 1 |
| Sciarra, A | 1 |
| Koyanagi, T; Okamura, K; Takamatsu, T | 1 |
| Blondin, P; Buzelin, JM; Hebert, M | 1 |
| Brasso, K; Flyger, H; Hald, T; Hansen, BJ; Meyhoff, HH; Mortensen, S; Nordling, J; Schou, J; Thorup Andersen, J; Walter, S | 1 |
| Flyger, H; Hansen, BJ; Mensink, HJ; Meyhoff, HH; Mortensen, S | 1 |
| D'Armiento, M; Damiano, R; De Sio, M; Mattace Raso, D; Perdonà, S; Santonastaso, C | 1 |
| Comet, D; Grange, JC; Lukacs, B; Thibault, P | 1 |
| Flyger, H; Hald, T; Hansen, BJ; Hendolin, N; Mensink, HJ; Mortensen, S; Nordling, J; Riehmann, M | 1 |
| Cologna, A; Kaplan, SA; Kohn, IJ; Martins, AC; Reis, RB; Suaid, HJ; Te, AE | 1 |
| Attali, P; Bensadoun, H; Delauche-Cavallier, MC; Jardin, A | 1 |
| Jardin, A; Laval, KU; van Cangh, P; van Kerrebroeck, P | 1 |
| Alfaro, V; Badiella, L; Fernández-Hernando, N; Guil, M; Sánchez-Chapado, M | 1 |
| Alfaro, V; Badiella, LI; Fernández-Hernando, N; Guil, M; Sánchez-Chapado, M | 1 |
| Roehrborn, CG | 1 |
| Höfner, K; Jonas, U | 1 |
| Bolzano, K | 1 |
| Attali, P; Delauche-Cavallier, MC; Teillac, P | 1 |
| Kaneko, S; Koyanagi, T; Kumamoto, Y; Maru, A; Nishizawa, O; Orikasa, S; Togashi, M; Tsuchida, S; Tsukamoto, T; Yachiku, S | 1 |
| Aso, Y; Honma, Y; Koyanagi, T; Maru, A; Miyake, K; Orikasa, S; Shimazaki, J; Soma, F; Togashi, M; Yasuda, K | 1 |
| Kondo, A; Mitsuya, H; Otani, T; Takita, T | 1 |
| Aso, Y; Ishibashi, A; Koshiba, K; Kumamoto, Y; Nishizawa, O; Ogawa, A; Tomita, Y; Tsuchida, S; Tsukamoto, T; Yokoyama, E | 1 |
| Jardin, A | 1 |
| Bérard, E; Cramer, P; Depassio, J; Neveux, E; Régnier, F | 1 |
2 review(s) available for quinazolines and Urination Disorders
| Article | Year |
|---|---|
Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Prostatic Hyperplasia; Quinazolines; Randomized Controlled Trials as Topic; Urination Disorders | 2005 |
Alfuzosin: a clinically uroselective alpha1-blocker.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Aged; Animals; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Male; Middle Aged; Prostate; Prostatic Hyperplasia; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome; Urination Disorders | 2002 |
23 trial(s) available for quinazolines and Urination Disorders
| Article | Year |
|---|---|
Effect of alfuzosin on female primary bladder neck obstruction.
Topics: Adrenergic alpha-Antagonists; Female; Humans; Middle Aged; Patient Satisfaction; Prospective Studies; Quality of Life; Quinazolines; Treatment Outcome; Urinary Bladder Neck Obstruction; Urination Disorders; Urodynamics | 2009 |
Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Drug Therapy, Combination; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Prostatic Hyperplasia; Purines; Quinazolines; Sildenafil Citrate; Sulfones; Urination Disorders | 2012 |
Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Doxazosin; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Treatment Outcome; Urination Disorders; Urodynamics | 2004 |
Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction.
Topics: Adrenergic alpha-Antagonists; Aged; Ejaculation; Humans; Male; Pain; Penile Erection; Quality of Life; Quinazolines; Sexual Dysfunction, Physiological; Treatment Outcome; Urinary Bladder Neck Obstruction; Urination Disorders | 2005 |
Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Single-Blind Method; Sulfonamides; Tamsulosin; Treatment Outcome; Urination Disorders | 2005 |
Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combination; Erectile Dysfunction; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Pilot Projects; Piperazines; Prostatic Hyperplasia; Purines; Quinazolines; Sildenafil Citrate; Sulfones; Treatment Outcome; Urination Disorders | 2007 |
Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Quinazolines; Urination; Urination Disorders | 1993 |
Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Surveys and Questionnaires; Urination Disorders | 1995 |
Symptomatic outcome of transurethral prostatectomy, alpha-blockade and placebo in the treatment of benign prostatic hyperplasia. Evaluation of treatment with the Danish Prostatic Symptom Score (DAN-PSS-1) system. The ALFECH Study Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Follow-Up Studies; Humans; Male; Middle Aged; Postoperative Complications; Prostatectomy; Prostatic Hyperplasia; Quality of Life; Quinazolines; Urinary Bladder Neck Obstruction; Urination Disorders; Urodynamics | 1996 |
[Role of alfuzosin in the treatment of functional voiding disorders in women].
Topics: Adolescent; Adult; Aged; Female; Humans; Middle Aged; Quinazolines; Urination Disorders | 1997 |
Comparison of the Danish Prostatic Symptom Score with the International Prostatic Symptom Score, the Madsen-Iversen and Boyarsky symptom indexes. ALFECH Study Group.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Humans; Hyperthermia, Induced; Male; Microwaves; Prostatic Hyperplasia; Quality of Life; Quinazolines; Severity of Illness Index; Single-Blind Method; Surveys and Questionnaires; Treatment Outcome; Urination Disorders | 1998 |
Intermittent alpha-blocker therapy in the treatment of men with lower urinary tract symptoms.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Quinazolines; Urination Disorders; Urodynamics | 1998 |
Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group.
Topics: Adrenergic alpha-Antagonists; Aged; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Urination Disorders; Urodynamics | 1993 |
Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.
Topics: Adrenergic alpha-Antagonists; Aged; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Safety; Urination Disorders | 2000 |
Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3,095 Spanish patients evaluated during general practice.
Topics: Adrenergic alpha-Antagonists; Aged; Analysis of Variance; Blood Pressure Monitoring, Ambulatory; Delayed-Action Preparations; Evaluation Studies as Topic; Family Practice; Follow-Up Studies; Humans; Male; Middle Aged; Patient Compliance; Prostatic Hyperplasia; Quality of Life; Quinazolines; Spain; Treatment Outcome; Urination Disorders | 2000 |
The clinical uroselectivity of alfuzosin is not significantly affected by the age of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Age Factors; Aged; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; Treatment Outcome; Urination Disorders | 2000 |
Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Canada; Double-Blind Method; Drug Administration Schedule; Humans; Hypertension; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; United States; Urination; Urination Disorders | 2001 |
Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. DUALF Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Time Factors; Urination; Urination Disorders; Urodynamics | 1992 |
[A double-blind trial on the effect of bunazosin hydrochloride for the symptoms of benign prostatic hypertrophy].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Alanine; Chi-Square Distribution; Double-Blind Method; Drug Combinations; Glutamates; Glycine; Humans; Japan; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Urination; Urination Disorders | 1990 |
[Clinical evaluation of bunazosin hydrochloride for the treatment of voiding disturbances due to neurogenic bladder--a double-blind study].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Bethanechol; Bethanechol Compounds; Chi-Square Distribution; Double-Blind Method; Female; Humans; Japan; Male; Middle Aged; Quinazolines; Urinary Bladder, Neurogenic; Urination; Urination Disorders | 1990 |
[Clinical study of bunazosin hydrochloride, an alpha 1-adrenergic blocker, in benign prostatic obstruction and neurogenic bladder dysfunction].
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation; Humans; Male; Middle Aged; Prostatic Diseases; Prostatic Hyperplasia; Quinazolines; Urinary Bladder, Neurogenic; Urination; Urination Disorders | 1987 |
[A double-blind trial on the effect of alpha-adrenergic blocker (bunazosin hydrochloride) in the symptomatic treatment of prostatism].
Topics: Adrenergic alpha-Antagonists; Aged; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Sympathetic Nervous System; Urination; Urination Disorders | 1987 |
[Efficacy of an alpha-blocker, alfuzosin, on urinary disorders in men with prostatic adenoma. Intermediate results of a European multicenter study].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Europe; Humans; Male; Middle Aged; Multicenter Studies as Topic; Prostatic Hyperplasia; Quinazolines; Random Allocation; Urination Disorders | 1988 |
15 other study(ies) available for quinazolines and Urination Disorders
| Article | Year |
|---|---|
Re: Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Humans; Male; Phosphodiesterase Inhibitors; Piperazines; Prostatic Hyperplasia; Quinazolines; Sulfones; Urination Disorders | 2013 |
[Our experience with the use of alpha-lithic therapy in the treatment of voiding dysfunction].
Topics: Adrenergic alpha-1 Receptor Antagonists; Child; Child, Preschool; Doxazosin; Female; Humans; Male; Quinazolines; Retrospective Studies; Urination Disorders | 2010 |
A current review of medical therapy for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Algorithms; Azasteroids; Cholestenone 5 alpha-Reductase; Doxazosin; Drug Therapy, Combination; Dutasteride; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Urination Disorders | 2004 |
A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus; Doxazosin; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Probability; Prostatic Hyperplasia; Quinazolines; Reference Values; Retrospective Studies; Risk Assessment; Severity of Illness Index; Sulfonamides; Tamsulosin; Treatment Outcome; Urination Disorders; Urodynamics | 2004 |
Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Urinary Retention; Urination Disorders | 2005 |
Early symptom improvement of benign prostatic hyperplasia (BPH) treated with once daily alfuzosin.
Topics: Adrenergic alpha-Antagonists; Delayed-Action Preparations; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; Urination Disorders | 2005 |
Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction.
Topics: Adrenergic alpha-Antagonists; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Erectile Dysfunction; Humans; Male; Middle Aged; Patient Satisfaction; Prognosis; Prospective Studies; Quinazolines; Severity of Illness Index; Treatment Outcome; Urinary Bladder Neck Obstruction; Urination Disorders | 2005 |
Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily.
Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Complications; Drug Administration Schedule; Humans; Hypertension; Male; Middle Aged; Myocardial Ischemia; Quinazolines; Urination Disorders | 2006 |
Dynamic variables: novel and perhaps better predictors of progression in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Disease Progression; Humans; Male; Prostatic Hyperplasia; Quinazolines; Risk Factors; Urination Disorders | 2006 |
Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Urinary Retention; Urination Disorders | 2006 |
Lower urinary tract symptoms (LUTS) and sexual dysfunction (SD): new targets for new combination therapies?
Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Drug Therapy, Combination; Enzyme Inhibitors; Erectile Dysfunction; Humans; Male; Middle Aged; Piperazines; Prevalence; Prostatic Hyperplasia; Purines; Quality of Life; Quinazolines; Risk Factors; Sildenafil Citrate; Sulfones; Urination Disorders | 2007 |
[Management of chronic spinal cord injury patients with prazosin].
Topics: Adult; Chronic Disease; Female; Humans; Male; Middle Aged; Prazosin; Quinazolines; Spinal Cord Injuries; Urination Disorders; Urodynamics | 1983 |
Construction and validation of a short-form benign prostatic hypertrophy health-related quality-of-life questionnaire. BPH Group in General Practice.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Anxiety; Case-Control Studies; Cohort Studies; Cross-Sectional Studies; Humans; Longitudinal Studies; Male; Middle Aged; Perception; Prostatic Hyperplasia; Psychometrics; Quality of Life; Quinazolines; Sensitivity and Specificity; Sexual Behavior; Surveys and Questionnaires; Urination Disorders | 1997 |
[A clinical study with prazosin].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Benzothiadiazines; Depression; Diuretics; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Muscle Contraction; Muscle Relaxation; Prazosin; Quinazolines; Sexual Behavior; Sodium Chloride Symporter Inhibitors; Urination Disorders | 1978 |
Bladder-neck opening test in spinal cord injury patients using a new i.v. alpha-blocking agent, alfuzosin.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Female; Humans; Injections, Intravenous; Male; Middle Aged; Quinazolines; Radiography; Spinal Cord Injuries; Urinary Bladder; Urination; Urination Disorders; Urodynamics | 1989 |